Please ensure Javascript is enabled for purposes of website accessibility

Why Shares of Cardiff Oncology Rose on Monday

By Jim Halley – Sep 13, 2021 at 9:00PM

Key Points

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

An insider buy and positive data may have boosted optimism.

What happened

Cardiff Oncology (CRDF 6.08%) , a clinical-stage biotech company specializing in new cancer treatments, saw its share price rise as high as $7.18 on Monday. It closed the day at $6.74, up about 7% from its previous close.

So what

Over the past year, the stock's per-share price has ranged from $4.88 to as high as $25.50. On Friday, investors learned that the company's CFO, James E. Levine, bought 30,000 shares of the stock at $6.47 a share.

The company also presented positive phase 1b/2 trial news last week regarding onvansertib, its lead pipeline candidate. The drug is being tested with a chemotherapy drug combination called FOLFIRI and a non-chemotherapeutic drug called Avastin (bevacizumab). Combined with FOLFIRI and Avastin, onvansertib is showing promise as a second-line treatment option for patients with KRAS-mutated metastatic colorectal cancer.

The company said that seven of 19 patients treated in the trial had a confirmed partial response to the drug therapy by the data cutoff date.

A scientist analyzes medical sample in a laboratory.

Image source: Getty Images.

Now what

Cardiff doesn't have any marketed drugs yet and does not turn a profit.

The company has a market cap of $249.18 million, so it doesn't take much action for the stock's price to jump -- or fall. Investors seem to be excited that insiders are positive about the company, but ultimately, until more conclusive trial details come in, this stock is pretty speculative. Levine joined the company last month along with Chief Medical Officer Katherine L. Ruffner.

If onvansertib is approved by the FDA, though, that would be a big deal for Cardiff. According to the American Cancer Society, colorectal cancer is the third-leading cause of cancer death in both men and women, and the second overall cause when both sexes are combined.

In the second quarter, the company reported a loss of $6.9 million. The biotech company also reported that it only has $10.5 million in cash, so its cash level is a concern.

Jim Halley has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Stocks Mentioned

Cardiff Oncology, Inc. Stock Quote
Cardiff Oncology, Inc.
$1.57 (6.08%) $0.09

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.